PMID- 7539236
OWN - NLM
STAT- MEDLINE
DCOM- 19950623
LR  - 20131121
IS  - 0250-7005 (Print)
IS  - 0250-7005 (Linking)
VI  - 15
IP  - 2
DP  - 1995 Mar-Apr
TI  - Radiotherapy plus carboplatin and teniposide in patients with brain metastases 
      from non small cell lung cancer.
PG  - 517-9
AB  - BACKGROUND: The role of chemotherapy alone or added to radiation treatment for 
      the palliation of multiple, unresectable brain metastases from non small cell 
      lung cancer (NSCLC), is not yet well defined. Carboplatin and teniposide, 
      however, are an interesting combination in this setting since they are active in 
      NSCLC and because of encouraging results against brain metastases in other tumor 
      types. METHODS: Twenty patients with brain metastases from NSCLC were treated 
      with whole brain irradiation (total dose of 45 Gy) and chemotherapy (carboplatin, 
      300 mg/sm on day 1 and teniposide, 60 mg/sm on days 1, 2 and 3). RESULTS: Nine 
      patients (45%) showed a complete remission of neurologic symptoms, and 7 (35%) an 
      improvement. Neurologic signs disappeared in 8 patients (40%) and improved in 7 
      (35%). Three patients (15%) had partial (50%) regression of brain metastases at 
      CT scan, and also showed response in other tumor sites. One other patient had a 
      response of chest and liver lesions, while the cerebral metastases remained 
      stable. Median survival was 7 months with a range of 1-9 months. Toxicity was 
      mild, with no toxic deaths. CONCLUSIONS: Aggressive treatment can be taken into 
      consideration also in the case of NSCLC patients with brain metastases and 
      negative prognostic features. Their participation in clinical trials should be 
      encouraged, since this will allow definition of the contribution of combined 
      radiotherapy, chemotherapy and supportive care to the quality and duration of the 
      patient's life.
FAU - Pronzato, P
AU  - Pronzato P
AD  - U.O. Oncologia Medica, Ospedale S. Andrea, La Spezia, Italy.
FAU - Bruna, F
AU  - Bruna F
FAU - Neri, E
AU  - Neri E
FAU - Roveri, D
AU  - Roveri D
FAU - Trabucchi, A
AU  - Trabucchi A
FAU - Vanoli, M
AU  - Vanoli M
FAU - Vigani, A
AU  - Vigani A
FAU - Vaira, F
AU  - Vaira F
FAU - Losardo, P
AU  - Losardo P
FAU - Bertelli, G
AU  - Bertelli G
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 7S5I7G3JQL (Dexamethasone)
RN  - 957E6438QA (Teniposide)
RN  - BG3F62OND5 (Carboplatin)
RN  - YQE403BP4D (Phenobarbital)
SB  - IM
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Brain Neoplasms/drug therapy/mortality/radiotherapy/*secondary
MH  - Carboplatin/administration & dosage
MH  - Carcinoma, Non-Small-Cell Lung/drug therapy/mortality/radiotherapy/*secondary
MH  - Combined Modality Therapy
MH  - *Cranial Irradiation
MH  - Dexamethasone/therapeutic use
MH  - Female
MH  - Humans
MH  - Liver Neoplasms/drug therapy/secondary
MH  - Lung Neoplasms/*pathology
MH  - Male
MH  - Middle Aged
MH  - *Palliative Care
MH  - Phenobarbital/therapeutic use
MH  - Prognosis
MH  - *Radioisotope Teletherapy
MH  - Remission Induction
MH  - Survival Analysis
MH  - Teniposide/administration & dosage
MH  - Treatment Outcome
EDAT- 1995/03/01 00:00
MHDA- 1995/03/01 00:01
CRDT- 1995/03/01 00:00
PHST- 1995/03/01 00:00 [pubmed]
PHST- 1995/03/01 00:01 [medline]
PHST- 1995/03/01 00:00 [entrez]
PST - ppublish
SO  - Anticancer Res. 1995 Mar-Apr;15(2):517-9.